These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2659 related items for PubMed ID: 15657900

  • 1. Pharmacological and small interference RNA-mediated inhibition of breast cancer-associated fatty acid synthase (oncogenic antigen-519) synergistically enhances Taxol (paclitaxel)-induced cytotoxicity.
    Menendez JA, Vellon L, Colomer R, Lupu R.
    Int J Cancer; 2005 May 20; 115(1):19-35. PubMed ID: 15657900
    [Abstract] [Full Text] [Related]

  • 2. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB.
    Menendez JA, Mehmi I, Atlas E, Colomer R, Lupu R.
    Int J Oncol; 2004 Mar 20; 24(3):591-608. PubMed ID: 14767544
    [Abstract] [Full Text] [Related]

  • 3. RNA interference-mediated silencing of the p53 tumor-suppressor protein drastically increases apoptosis after inhibition of endogenous fatty acid metabolism in breast cancer cells.
    Menendez JA, Lupu R.
    Int J Mol Med; 2005 Jan 20; 15(1):33-40. PubMed ID: 15583825
    [Abstract] [Full Text] [Related]

  • 4. Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene.
    Menendez JA, Vellon L, Lupu R.
    Ann Oncol; 2005 Aug 20; 16(8):1253-67. PubMed ID: 15870086
    [Abstract] [Full Text] [Related]

  • 5. Overexpression and hyperactivity of breast cancer-associated fatty acid synthase (oncogenic antigen-519) is insensitive to normal arachidonic fatty acid-induced suppression in lipogenic tissues but it is selectively inhibited by tumoricidal alpha-linolenic and gamma-linolenic fatty acids: a novel mechanism by which dietary fat can alter mammary tumorigenesis.
    Menendez JA, Ropero S, Mehmi I, Atlas E, Colomer R, Lupu R.
    Int J Oncol; 2004 Jun 20; 24(6):1369-83. PubMed ID: 15138577
    [Abstract] [Full Text] [Related]

  • 6. Inhibition of tumor-associated fatty acid synthase activity enhances vinorelbine (Navelbine)-induced cytotoxicity and apoptotic cell death in human breast cancer cells.
    Menendez JA, Colomer R, Lupu R.
    Oncol Rep; 2004 Aug 20; 12(2):411-22. PubMed ID: 15254710
    [Abstract] [Full Text] [Related]

  • 7. A novel CYR61-triggered 'CYR61-alphavbeta3 integrin loop' regulates breast cancer cell survival and chemosensitivity through activation of ERK1/ERK2 MAPK signaling pathway.
    Menendez JA, Vellon L, Mehmi I, Teng PK, Griggs DW, Lupu R.
    Oncogene; 2005 Jan 27; 24(5):761-79. PubMed ID: 15592521
    [Abstract] [Full Text] [Related]

  • 8. Asiatic acid, a triterpene, induces apoptosis and cell cycle arrest through activation of extracellular signal-regulated kinase and p38 mitogen-activated protein kinase pathways in human breast cancer cells.
    Hsu YL, Kuo PL, Lin LT, Lin CC.
    J Pharmacol Exp Ther; 2005 Apr 27; 313(1):333-44. PubMed ID: 15626723
    [Abstract] [Full Text] [Related]

  • 9. DNA topoisomerase IIalpha (TOP2A) inhibitors up-regulate fatty acid synthase gene expression in SK-Br3 breast cancer cells: in vitro evidence for a 'functional amplicon' involving FAS, Her-2/neu and TOP2A genes.
    Menendez JA, Vellon L, Lupu R.
    Int J Mol Med; 2006 Dec 27; 18(6):1081-7. PubMed ID: 17089011
    [Abstract] [Full Text] [Related]

  • 10. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.
    Oliveras-Ferraros C, Vazquez-Martin A, López-Bonet E, Martín-Castillo B, Del Barco S, Brunet J, Menendez JA.
    Int J Oncol; 2008 Dec 27; 33(6):1165-76. PubMed ID: 19020749
    [Abstract] [Full Text] [Related]

  • 11. The role of ERK 1/2 and p38 MAP-kinase pathways in taxol-induced apoptosis in human ovarian carcinoma cells.
    Seidman R, Gitelman I, Sagi O, Horwitz SB, Wolfson M.
    Exp Cell Res; 2001 Aug 01; 268(1):84-92. PubMed ID: 11461121
    [Abstract] [Full Text] [Related]

  • 12. Taxol-induced apoptosis depends on MAP kinase pathways (ERK and p38) and is independent of p53.
    Bacus SS, Gudkov AV, Lowe M, Lyass L, Yung Y, Komarov AP, Keyomarsi K, Yarden Y, Seger R.
    Oncogene; 2001 Jan 11; 20(2):147-55. PubMed ID: 11313944
    [Abstract] [Full Text] [Related]

  • 13. Glucocorticoid receptor-induced MAPK phosphatase-1 (MPK-1) expression inhibits paclitaxel-associated MAPK activation and contributes to breast cancer cell survival.
    Wu W, Pew T, Zou M, Pang D, Conzen SD.
    J Biol Chem; 2005 Feb 11; 280(6):4117-24. PubMed ID: 15590693
    [Abstract] [Full Text] [Related]

  • 14. Proteasome inhibitors induce a p38 mitogen-activated protein kinase (MAPK)-dependent anti-apoptotic program involving MAPK phosphatase-1 and Akt in models of breast cancer.
    Shi YY, Small GW, Orlowski RZ.
    Breast Cancer Res Treat; 2006 Nov 11; 100(1):33-47. PubMed ID: 16807678
    [Abstract] [Full Text] [Related]

  • 15. The investigational Aurora kinase A inhibitor alisertib (MLN8237) induces cell cycle G2/M arrest, apoptosis, and autophagy via p38 MAPK and Akt/mTOR signaling pathways in human breast cancer cells.
    Li JP, Yang YX, Liu QL, Pan ST, He ZX, Zhang X, Yang T, Chen XW, Wang D, Qiu JX, Zhou SF.
    Drug Des Devel Ther; 2015 Nov 11; 9():1627-52. PubMed ID: 25834401
    [Abstract] [Full Text] [Related]

  • 16. Inhibition of tumor-associated fatty acid synthase activity antagonizes estradiol- and tamoxifen-induced agonist transactivation of estrogen receptor (ER) in human endometrial adenocarcinoma cells.
    Menendez JA, Oza BP, Atlas E, Verma VA, Mehmi I, Lupu R.
    Oncogene; 2004 Jun 17; 23(28):4945-58. PubMed ID: 15094777
    [Abstract] [Full Text] [Related]

  • 17. Inactivation of the antiapoptotic phosphatidylinositol 3-kinase-Akt pathway by the combined treatment of taxol and mitogen-activated protein kinase kinase inhibition.
    MacKeigan JP, Taxman DJ, Hunter D, Earp HS, Graves LM, Ting JP.
    Clin Cancer Res; 2002 Jul 17; 8(7):2091-9. PubMed ID: 12114408
    [Abstract] [Full Text] [Related]

  • 18. Pharmacological inhibition of fatty acid synthase (FAS): a novel therapeutic approach for breast cancer chemoprevention through its ability to suppress Her-2/neu (erbB-2) oncogene-induced malignant transformation.
    Menendez JA, Mehmi I, Verma VA, Teng PK, Lupu R.
    Mol Carcinog; 2004 Nov 17; 41(3):164-78. PubMed ID: 15390078
    [Abstract] [Full Text] [Related]

  • 19. Down-regulation of cyclin-dependent kinase-4 and MAPK through estrogen receptor mediated cell cycle arrest in human breast cancer induced by gold nanoparticle tagged toxin protein NKCT1.
    Bhowmik T, Gomes A.
    Chem Biol Interact; 2017 Apr 25; 268():119-128. PubMed ID: 28322778
    [Abstract] [Full Text] [Related]

  • 20. The estrogenic activity of synthetic progestins used in oral contraceptives enhances fatty acid synthase-dependent breast cancer cell proliferation and survival.
    Menendez JA, Oza BP, Colomer R, Lupu R.
    Int J Oncol; 2005 Jun 25; 26(6):1507-15. PubMed ID: 15870863
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 133.